搜索
Axsome Therapeutics Inc
AXSM添加自选
231.585USD
+7.555+3.37%
交易中 （美东）报价延迟15分钟
11.91B总市值
亏损市盈率 TTM
查看详细走势图
盘中分时
1分
30分
1小时
日k
周k
月k
日k
今天
+3.37%
5天
+3.82%
1月
+30.02%
6月
+64.41%
今年开始到现在
+26.80%
1年
+110.23%
TradingKey Axsome Therapeutics Inc股票评分
单位: USD 更新时间: 2026-05-12操作建议
Axsome Therapeutics Inc当前公司基本面数据相对健康，最新ESG披露属于行业中等水平。增长潜力很大。当前估值合理，在药品行业排名22/156位。机构持股占比非常高，近一月多位分析师给出公司评级为买入。最高目标价267.35。中期看，股价处于上升通道。近一个月，市场表现很强，技术面和基本面综合得分较高，很强的走势得到基本面和技术面的印证。目前股价在压力位和支撑位之间，可以做区间波段操作。
Axsome Therapeutics Inc评分
压力支撑
由于公司未披露，未能获取相关数据
多维评测
本期评分
上期评分
公司舆情
过去24小时
热度
过冷
过热
中性
Axsome Therapeutics Inc亮点
亮点风险
Axsome Therapeutics, Inc. is a biopharmaceutical company. The Company is focused on the development and commercialization of medicines for people living with central nervous system (CNS) conditions. The Company's commercial products include Auvelity, Sunosi and Symbravo. It is also advancing a diversified, late-stage pipeline of product candidates for serious neurological and psychiatric conditions, which include AXS-05, AXS-12, AXS-14 and AXS-17. Auvelity (dextromethorphan-bupropion) is an oral, N-methyl-D-aspartate (NMDA) receptor antagonist with multimodal activity indicated for the treatment of major depressive disorder (MDD). Sunosi (solriamfetol) is an oral medication indicated for the treatment of excessive daytime sleepiness (EDS), in patients with narcolepsy or obstructive sleep apnea. Symbravo (meloxicam and rizatriptan, 20 mg/10mg tablets) is an oral, single-dose medicine approved for the acute treatment of migraine with or without aura in adults.
业绩高增长
公司营业收入稳步增长，连续3年增长135.96%
估值低估
公司最新PE估值-60.11，处于3年历史低位
机构减仓
最新机构持股39.43M股，环比减少8.10%
詹姆斯·西蒙斯持仓
明星投资者詹姆斯·西蒙斯持仓，最新持仓市值170.00K
活跃度增加
近期活跃度增加，过去20天平均换手率0.35
分析师目标
根据
21
位分析师
买入
评级
267.350
目标均价
+22.99%
涨幅空间
数据免责声明：分析师评级与目标价由LSEG提供，仅供参考，不应当作投资建议
Axsome Therapeutics Inc新闻
即将为您带来更多新闻，敬请期待。。。
财务指标
每股收益
由于公司未披露，未能获取相关数据
营业总收入
由于公司未披露，未能获取相关数据
Axsome Therapeutics Inc简介
Axsome Therapeutics, Inc. is a biopharmaceutical company. The Company is focused on the development and commercialization of medicines for people living with central nervous system (CNS) conditions. The Company's commercial products include Auvelity, Sunosi and Symbravo. It is also advancing a diversified, late-stage pipeline of product candidates for serious neurological and psychiatric conditions, which include AXS-05, AXS-12, AXS-14 and AXS-17. Auvelity (dextromethorphan-bupropion) is an oral, N-methyl-D-aspartate (NMDA) receptor antagonist with multimodal activity indicated for the treatment of major depressive disorder (MDD). Sunosi (solriamfetol) is an oral medication indicated for the treatment of excessive daytime sleepiness (EDS), in patients with narcolepsy or obstructive sleep apnea. Symbravo (meloxicam and rizatriptan, 20 mg/10mg tablets) is an oral, single-dose medicine approved for the acute treatment of migraine with or without aura in adults.
公司代码AXSM
公司Axsome Therapeutics Inc
CEOTabuteau (Herriot)
网址https://www.axsome.com/
相关品种
